Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- Oil rises over 3% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
Heron Therapeutics (HRTX) PT Lowered to $34 at Cowen; Launch Likely Pushed to Mid-2021
June 29, 2020 10:56 AM EDTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $34.00 (from $39.00) while maintaining an Outperform rating.
The analyst commented, "Heron received a CRL for HTX-011 requesting additional nonclinical information. The CRL is related to excipient exposure levels from... More
Heron Therapeutics (HRTX) said defended at Evercore ISI
June 29, 2020 10:14 AM EDTHeron Therapeutics (NASDAQ: HRTX) said defended at Evercore ISI, saying they are buyers on weakness.
... MoreHeron Therapeutics (HRTX) to Resume Trading at 9:10 a.m.
June 29, 2020 8:48 AM EDTHeron Therapeutics (NASDAQ: HRTX) to Resume Trading at 9:10 a.m.
